Literature DB >> 10449808

In vivo gammadelta T cell priming to mycobacterial antigens by primary Mycobacterium tuberculosis infection and exposure to nonpeptidic ligands.

F Poccia1, M Malkovsky, A Pollak, V Colizzi, G Sireci, A Salerno, F Dieli.   

Abstract

BACKGROUND: The recognition of phosphorylated nonpeptidic microbial metabolites by Vgamma9Vdelta2 T cells does not appear to require the presence of MHC molecules or antigen processing, permitting rapid responses against microbial pathogens. These may constitute an important area of natural anti-infectious immunity. To provide evidence of their involvement in immune reactivities against mycobacteria, we measured the responsiveness of peripheral blood Vgamma9Vdelta2 T cells in children with primary Mycobacterium tuberculosis (MTB) infections.
MATERIALS AND METHODS: Peripheral blood mononuclear cells from 22 children with MTB infections and 16 positivity of tuberculin (PPD)-negative healthy children were exposed to nonpeptidic antigens in vitro and the reactivity of the Vgamma9Vdelta2 T cell subset with these antigens was determined using proliferation and cytokine assays. Also, responses of gammadelta T cells from rhesus monkeys stimulated with phosphoantigens in vivo were measured.
RESULTS: The Vgamma9Vdelta2 T cell responses were highly increased in infected children in comparison with age-matched controls. This augmented Vgamma9Vdelta2 T cell reactivity subsided after successful antibiotic chemotherapy, suggesting that persistent exposure to mycobacterial antigens is required for the maintenance of gammadelta T cell activation in vivo. The in vivo reactivity of Vgamma9Vdelta2 T cells to phosphoantigens was also analyzed in a rhesus monkey model system. Intravenous injections of phosphoantigens induced an activated state of simian Vgamma9Vdelta2 T cells which decreased after 2 months, i.e., with a time course similar to that seen in MTB-infected children.
CONCLUSIONS: The increased reactivity of Vgamma9Vdelta2 T cells to phosphoantigens appears to be dependent on constant antigenic exposure. Consequently, the assessment of Vgamma9Vdelta2 responses may be useful for monitoring the efficacy of antimycobacterial therapies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449808      PMCID: PMC2230443     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  20 in total

1.  Bacille Calmette-Guérin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype.

Authors:  D F Hoft; R M Brown; S T Roodman
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

2.  Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes.

Authors:  M B Brenner; J McLean; H Scheft; J Riberdy; S L Ang; J G Seidman; P Devlin; M S Krangel
Journal:  Nature       Date:  1987 Feb 19-25       Impact factor: 49.962

3.  Characterization of serologic and cell-mediated reactivity of a 38-kDa antigen isolated from Mycobacterium tuberculosis.

Authors:  G V Kadival; S D Chaparas; D Hussong
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

4.  Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.

Authors:  Y Tanaka; C T Morita; Y Tanaka; E Nieves; M B Brenner; B R Bloom
Journal:  Nature       Date:  1995-05-11       Impact factor: 49.962

5.  Early activation of human V gamma 9V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands.

Authors:  F Lang; M A Peyrat; P Constant; F Davodeau; J David-Ameline; Y Poquet; H Vié; J J Fournié; M Bonneville
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

6.  Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands.

Authors:  P Constant; F Davodeau; M A Peyrat; Y Poquet; G Puzo; M Bonneville; J J Fournié
Journal:  Science       Date:  1994-04-08       Impact factor: 47.728

7.  Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells.

Authors:  P Fisch; M Malkovsky; S Kovats; E Sturm; E Braakman; B S Klein; S D Voss; L W Morrissey; R DeMars; W J Welch
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

8.  T cell dependence of macrophage activation and mobilization during infection with Mycobacterium tuberculosis.

Authors:  R J North
Journal:  Infect Immun       Date:  1974-07       Impact factor: 3.441

9.  Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire.

Authors:  C M Parker; V Groh; H Band; S A Porcelli; C Morita; M Fabbi; D Glass; J L Strominger; M B Brenner
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

10.  The primary response of human gamma/delta + T cells to Mycobacterium tuberculosis is restricted to V gamma 9-bearing cells.

Authors:  D Kabelitz; A Bender; T Prospero; S Wesselborg; O Janssen; K Pechhold
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Human gamma delta T lymphocytes in HIV disease: effector functions and control by natural killer cell receptors.

Authors:  M L Gougeon; F Poccia; S Boullier
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens.

Authors:  Andrew M Hebbeler; Cristiana Cairo; Jean Saville Cummings; C David Pauza
Journal:  Cancer Immunol Immunother       Date:  2006-11-28       Impact factor: 6.968

Review 3.  Quest for correlates of protection against tuberculosis.

Authors:  Kamlesh Bhatt; Sheetal Verma; Jerrold J Ellner; Padmini Salgame
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

Review 4.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

5.  Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research.

Authors:  J A Langermans; P Andersen; D van Soolingen; R A Vervenne; P A Frost; T van der Laan; L A van Pinxteren; J van den Hombergh; S Kroon; I Peekel; S Florquin; A W Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

6.  Responses of bovine WC1(+) gammadelta T cells to protein and nonprotein antigens of Mycobacterium bovis.

Authors:  Michael D Welsh; Hilary E Kennedy; Allister J Smyth; R Martyn Girvin; Peter Andersen; John M Pollock
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  Antigens in tea-beverage prime human Vgamma 2Vdelta 2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses.

Authors:  Arati B Kamath; Lisheng Wang; Hiranmoy Das; Lin Li; Vernon N Reinhold; Jack F Bukowski
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-28       Impact factor: 11.205

8.  Phosphoantigen presentation by macrophages to mycobacterium tuberculosis--reactive Vgamma9Vdelta2+ T cells: modulation by chloroquine.

Authors:  Roxana E Rojas; Martha Torres; Jean-Jacques Fournié; Clifford V Harding; W Henry Boom
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

9.  A Subset of Protective γ9δ2 T Cells Is Activated by Novel Mycobacterial Glycolipid Components.

Authors:  Mei Xia; Danny C Hesser; Prithwiraj De; Isaac G Sakala; Charles T Spencer; Jay S Kirkwood; Getahun Abate; Delphi Chatterjee; Karen M Dobos; Daniel F Hoft
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

10.  CD3ε Expression Defines Functionally Distinct Subsets of Vδ1 T Cells in Patients With Human Immunodeficiency Virus Infection.

Authors:  Pádraic J Dunne; Christina O Maher; Michael Freeley; Katie Dunne; Andreea Petrasca; Judy Orikiiriza; Margaret R Dunne; Derval Reidy; Siobhan O'Dea; Aisling Loy; Jim Woo; Aideen Long; Thomas R Rogers; Fiona Mulcahy; Derek G Doherty
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.